This article discusses the development of homogeneous, miniaturized assays for the identification of novel kinase inhibitors from very large compound collections. In particular, the suitability of time-resolved fluorescence resonance energy transfer (TR-RET) based on phospho-specific antibodies, an antibody-independent fluorescence polarization (FP) approach using metal-coated beads (IMAP™ technology), and the determination of adenosine triphosphate consumption through chemiluminescence is evaluated. These readouts are compared with regard to assay sensitivity, compound interference, reagent consumption, and performance in a 1536-well format, and practical considerations for their application in primary screening or in the identification of kinase substrates are discussed. All of the tested technologies were found to be suitable for miniaturized high-throughput screening (HTS) in principle, but each of them has distinct limitations and advantages. Therefore, the target-specific selection of the most appropriate readout technology is recommended to ensure maximal relevance of HTS campaigns. (Journal of Biomolecular Screening 2006:617-633) 
INTRODUCTION
O VER THE PAST DECADE, kinases have emerged as one of the most important target classes for drug discovery and development because of their crucial role in cellular signaling. 1 Examples of kinase inhibitors that are now used in the clinic are imatinib mesylate (Gleevec™), which targets the tyrosine kinase BCR-ABL 2 ; gefitinib (Iressa™), an inhibitor of epidermal growth factor receptor-tyrosine kinase activity 3 ; and fasudil (Eril™), which targets the Ser/Thr kinase ROCK. 4 Although there are other compounds such as sorafenib (BAY 43-9006) or sutent (SU11248) in late development or clinical studies, 5, 6 the human genome contains many more kinases that are potential drug targets but have not been addressed so far. Thus, there is a need for assay technologies that allow reliable and effective screening of large compound libraries for kinase inhibitors. Because the number of compounds to be tested in such campaigns can easily exceed 10 6 and the supply of many target proteins is limited, high-throughput screening (HTS) is increasingly performed in miniaturized (1536-well) format, which restricts the applicable assay technologies. For example, filter-binding assays have traditionally been used to measure the kinase-catalyzed incorporation of radioactive phosphate into proteins but are not easily automated and miniaturized. The same considerations apply to plate-binding technologies such as enyzme-linked immunosorbent assay or DELFIA ® , which are typically performed in a 96-well or 384-well format. 7, 8 Instead, homogeneous assay formats are much better suited to miniaturization, as there still are no reliable devices to accurately remove liquids from 1536-well plates.
When applied to kinases, most of the homogeneous detection technologies rely on appropriate antibodies to detect the phosphorylated product of the reaction. 8 Therefore, a prerequisite for development of kinase assays with these methods is knowledge of a substrate that is phosphorylated by the kinase as well as a corresponding antibody that specifically recognizes the phosphorylated but not the unphosphorylated form of the peptide or protein. For tyrosine kinases, there are both generic substrates (typically copolymers of tyrosine with another amino acid) and generic antibodies against phosphotyrosine, whose binding affinities are not influenced by any surrounding amino acids. However, applying these technologies to serine/ threonine kinases is much less straightforward. The 2 major reasons for this are the much larger specificity of serine/threonine kinases for the peptide sequence of their substrates and the low immunogenicity of phosphoserine. The latter necessitates the generation of phosphorylation-specific antibodies against the respective substrate, which only rarely can be used for other kinase-substrate combinations. Although phosphorylationspecific antibodies are now commercially available against many of the established kinase substrates, identification of the correct substrate sequence and the generation of the corresponding phosphorylation-specific antibody still are rate limiting for the discovery of inhibitors against novel, genomics-derived kinase targets. Therefore, several generic and antibody-independent assay formats to measure serine/threonine kinases have been proposed over the past few years. 6 However, their applicability in highly miniaturized (1536-well) HTS has so far not been systematically explored.
Time-resolved fluorescence resonance energy transfer (TR-FRET) 9 has been successfully used for a number of years to screen for kinase inhibitors. It is based on the transfer of photons from a lanthanide complex (donor) to a suitable acceptor (Acc.) such as allophycocyanin 10 or cyanine 5 (Cy5), 11 when the 2 are in close proximity. This can be achieved by attaching one of the partners to a primary or secondary antibody and the other to streptavidin, which can bind a biotinylated peptide. If the europium complex donor is excited by a pulsed light source, its extremely long lifetime allows the separation of the TR-FRET signal from the light emitted by other fluorophores with a normal lifetime. Together with the large Stokes shift of the lanthanide fluorescence and the ratiometric nature of the readout, this reduces interference with the signal and falsepositive hits arising from autofluorescent compounds in the screening collection. 12 Fluorescence polarization (FP) 13 is also a well-established technology for miniaturized screening, 14 and like TR-FRET, it mostly uses phosphorylation-specific antibodies to detect the product of the kinase reaction. Although the first reports 15 directly used a fluorescent peptide as the kinase substrate, the enzyme activity is now typically monitored through competition of the (unlabeled) reaction product with a fluorescently-labeled tracer phosphopeptide. 8, 16 Recently, a novel, antibody-independent FP kinase assay technology named IMAP™ (immobilized metal ion affinity-based FP) has been introduced, which relies on metal-coated beads to capture and immobilize phosphate groups. 17, 18 This interaction strongly increases the polarization of an attached fluorophore, enabling an assay in which the kinase directly phosphorylates a fluorescently-labeled peptide rather than producing a competitor of binding. However, a prerequisite for this approach is knowledge of the respective substrate sequence and the possibility to fluorescently label the peptide without disturbing recognition by the kinase.
Another antibody-independent assay format relies on chemiluminescence to quantify the adenosine triphosphate (ATP) that remains after the kinase reaction has been stopped. Reportedly, the reproducibility of this technology is superior to that of the scintillation proximity assay format and equivalent to that of radioactive filter-binding experiments, although a counterassay is recommended to exclude compounds that interfere with the luciferase or the luminescence itself. 19 Several commercial suppliers offer luciferase-luciferin mixtures for this purpose, although it is not entirely clear whether the respective intellectual property is in the public domain. A kinase inhibitor will reduce the consumption of ATP and thus increase the luminescence signal. Arguably, this assay principle is at least as generic as the classical radiometric assay, as all kinases by definition use ATP to phosphorylate their substrates. Even kinases that phosphorylate substrates other than proteins (e.g., glycolytic metabolites or lipids) can be assayed by this approach.
This report critically compares the 3 homogeneous assay methods mentioned above ( Fig. 1) and highlights some essential considerations in developing miniaturized kinase assays. The criteria for this comparison include the sensitivity toward inhibitors, how easily an assay can be adapted to the enzymology of the respective kinase, and also the amount of enzyme needed. The miniaturization of assays to the 1536-well format, which is becoming a de facto industry standard for biochemical HTS, is a special focus as is the possibility to identify substrates for novel kinases.
MATERIALS AND METHODS

Reagents and devices
All reagents were of analytical grade or comparable. Eu complexes for labeling of antibodies were from Amersham (Cat. No. PA92004; Otelfingen, Switzerland); Eu-labeled secondary antibodies were from PerkinElmer (Cat. No. AD0083; Schwerzenbach, Switzerland) or CisBio International (Cat. No 61PARKLA; Bagnols sur Cèze, France). Luciferase/luciferin mixes were either from Promega (Cat. No. V6714, obtained through Catalys, Wallisellen, Switzerland), Cambrex (Cat. No. LT27-055; Nottingham, UK), or Sigma (Cat. No. FL-AA, obtained through Fluka, Buchs, Switzerland). Kinases 1 to 3 were purchased from Upstate (through LucernaChem, Luzern, Switzerland) or from ProQinase (Freiburg, Germany) or prepared by proprietary protocols in house. Their activity was not affected by DMSO concentrations up to at least 5% (v/v). Sequence-specific substrate peptides were obtained from ThermoElectron (Ulm, Germany) or from IRIS Biotech (Marktredwitz, Germany) either as purified biotinylated peptides or attached to resin for subsequent fluorescent labeling.
Unless otherwise indicated, all measurements were performed on an Analyst GT multimode reader (Molecular Devices, Sunnyvale, CA). Liquid was dispensed into 1536-well plates with either a Cartesian Synquad dispenser (Genomic Solutions, Huntingdon, UK) or a piezo-electric DINA™ nanodispenser (Evotec Technologies, Hamburg, Germany).
TR-FRET assay for kinase 1
This protocol is for a 1536-well HTS format. All experiments in a 384-well format used proportionally larger volumes or were performed as indicated in the figure legends. [CV]/well 1%; flash interval 1 × 2 ms; delay after flash 75 µs; integration time 100,000 µs; flashes/well 10; attenuator mode out). The readout was calculated as (acceptor counts/donor counts) × 1000. Slight modifications of this protocol were tested during assay development and are indicated in the figure legends.
TR-FRET assay for kinase 2
This protocol is for a 1536-well HTS format. All experiments in 384-well format used proportionally larger volumes or were performed as indicated in the figure legends. Into white polystyrene 1536-well plates (NUNC Cat. No. 264736), up to 100 nl of 90% DMSO/10% water containing the compound to be tested was dispensed using a modified Cartesian Hummingbird System. To this, 1.5 µl of 200 nM biotinylated substrate peptide, 300 µM ATP in 50 mM HEPES pH 7.4, 100 mM NaCl, 0.02% (v/v) Triton-X-100, 0.01% (w/v) BSA, 10 mM MgCl 2 , and 1 mM DTT was added with a Cartesian Synquad followed by addition of 1.5 µl of kinase 2 in the same buffer from a 2nd channel of the Cartesian Synquad. After the plate had been incubated for 120 min at room temperature, the reaction was stopped by adding 1.0 µl 125 mM EDTA (pH adjusted to 8.0 with NaOH) and 1.0 µl 12.5 nM Eu-labeled antiphosphopeptide antibody, 31.25 nM SA-APC in 50 mM HEPES pH 7.4, 100 mM NaCl, 0.02% (v/v) Triton-X-100, 0.01% (w/v) BSA, 10 mM MgCl 2 , and 1 mM DTT. After a further incubation of 40 min at room temperature, the plate was read on a Molecular Devices Analyst GT (dichroic UV 380 nm; excitation Eu-chelate 330 ± 35 nm; emission donor 615 ± 5 nm; emission acceptor 665 ± 5 nm; Z height middle of well, 10 flashes/well; flash interval 1 × 2 ms; target CV/well 1%; delay after flash 75 µs; integration time 1000 µs), and the readout was calculated as (acceptor counts/donor counts) × 1000. Slight modifications of this protocol were tested during assay development and are indicated in the figure legends.
Direct FP assay for kinase 1
For readout comparison experiments, kinase 1 was also measured in a direct FP assay format in black polystyrene 384well plates with a glass bottom (Greiner Cat. No. 7781896) on an Insight confocal fluorescence reader (Evotec Technologies, Hamburg, Germany). To this end, 5 µl of 4×-concentrated solution of the test compound (staurosporine or dye) was mixed with 5 µl 0.5 U/ml (or as indicated) kinase 1 and-after a 10-min preincubation-5 µl 400 µM ATP and 5 µl 400 nM (or as indicated) tetramethylrhodamine carboxylic acid (TAMRA)labeled crosstide (GRPRTSSFAEG 20 ), all in 50 mM Mops pH 7.2, 1 mM DTT, 10 mM MgCl 2 , 0.2 mM EDTA, 0.05% (v/v) Triton X-100, 0.01% (w/v) BSA. After a reaction of 90 min at room temperature, 60 µl of a 1:50 dilution of "classic" IMAP binding reagent (Molecular Devices, Sunnyvale, CA, USA Cat.
No. R8073) in binding buffer was added, and after a further incubation of 30 min at room temperature, the plate was read on a confocal fluorescence reader (Evotec Technologies Insight, excitation laser 535 nm, laser power 153 µW, FIDA coupling with black spot and polarizing filter, emission filter 590-60, 1 s measurement time, beam-scanner settings 100/25/250, detection cube with beam-splitter and polarizing filters). To enable comparison with data obtained on nonconfocal readers, polarization values were calculated from total intensities in the 2 channels rather than from individual fluorescence components. For determination of K M values, the amount of phosphopeptide formed was calculated from the polarization values according to the formula . 21 Slight modifications of this protocol were tested during assay development and are indicated in the figure legends.
Direct FP assay for kinase 2
This protocol is for a 1536-well HTS format. All experiments in a 384-well format used proportionally larger volumes or were performed as indicated in the figure legends. Into black 1536well polystyrene plates (NUNC, Roskilde, Denmark, Cat. No. 253601, or Packard Optiplate, Perkin Elmer, Schwerzenbach, Switzerland, Cat. No. 6005235), up to 100 nl of 90% DMSO/10% water containing the compound to be tested was dispensed using a modified Cartesian Hummingbird System. Subsequently, 1.5 µl of 6 µg/ml kinase 2 in assay buffer (10 mM Tris•HCl pH 7.4, 10 mm MgCl 2 , 0.01% [v/v] Triton X-100, 1 mM DTT) was added with a Cartesian Synquad. After a preincubation of 15 min, 1.5 µl reaction mix (1 µM TAMRA-labeled substrate peptide, 200 µM ATP in 10mM Tris•HCl pH 7.4, 10 mM MgCl 2 , 0.1% [v/v] Pluronic, 1 mM DTT) was added. After a reaction time of 90 to 120 min at room temperature in a humidified atmosphere, 3 µl of "progressive" IMAP binding reagent (Molecular Devices, Sunnyvale, CA, USA Cat. No. 6073) diluted 1:600 in a mixture of 95% binding buffer A, 5% binding buffer B was added using a Cartesian Synquad equipped with an agitated reservoir (Evotec Technologies, Hamburg, Germany). After the readout had developed for typically 60 min, the plate was measured on the Analyst GT in FP mode (lamp continuous, excitation filter 530-25, emission filter 580-10, target SD 1 mP, raw data counts/s, attenuator out, Z height middle of well/2.5 mm). Slight modifications of this protocol were tested during assay development and are indicated in the figure legends.
Chemiluminescence assay for kinase 1
For readout comparison experiments, kinase 1 was also measured in the chemiluminescence format in white polystyrene 384-well plates (Greiner Cat. No. 784075 obtained through Huber, Reinach, Switzerland). To this end, 5 µl of 200 µM peptide substrate, 20 µM ATP in 50 mM Mops pH 7.2,
1 mM DTT, 10 mM MgCl 2 , 0.2 mM EDTA, 0.05 % (v/v) Triton X-100, 0.01% (w/v) BSA, 10 µM Na 3 VO 4 , was mixed with 5 µl of a 2× solution of kinase 1 in the same buffer and incubated for the indicated times. After addition of 10 µl of Kinase-Glo luciferase/luciferin mixture (Promega Cat. No. V6174 obtained through Catalys, Wallisellen, Switzerland) and a further incubation of 10 min, the plate was read on the Analyst GT (200 ms/well, attenuator out, CV 1%, Z height 1 mm). Slight modifications of this protocol were tested during assay development and are indicated in the figure legends.
Chemiluminescence assay for kinase 3
This protocol is for a 1536-well HTS format. All experiments in a 384-well format used proportionally larger volumes or were performed as indicated in the figure legends. Into white polystyrene 1536-well plates (NUNC Cat. No. 264736), up to 100 nl 90% DMSO containing the compound to be tested was dispensed using a modified Cartesian Hummingbird System. Subsequently, 1.6 µl of 8.8 µg/ml (200 nM) kinase solution in 25mM Tris•HCl pH 7.4, 15 mM MgCl 2 , 10%(v/v) glycerol, 0.05% (v/v) Triton X-100, 1 mM EDTA, as well as 1.6 µl of a mixture containing 25 µM low-molecular-weight kinase substrate and 10 µM ATP in the same buffer were dispensed with a Cartesian Synquad. In control reactions, either kinase 3 was omitted or a substrate mix without ATP was used. After 60 min of incubation at room temperature, 1.8 µl of Kinase-Glo reagent (Promega Cat. No. V6174) or a similar mixture was added and after a further 10 min of incubation at room temperature, luminescence was read on the Analyst GT in luminescence mode (200 ms/well, attenuator out, CV 1%, Z height 1 mm). Slight modifications of this protocol were tested during assay development and are indicated in the figure legends.
Determination of kinetic parameters and curve fitting
Reaction velocities were determined by linear regression of the initial phase of time-course experiments. K M values were derived by fitting a hyperbolic function to a plot of reaction velocity over the concentration of the respective substrate using nonlinear least-squares regression. IC 50 values were derived by fitting a sigmoidal dose-response curve to a plot of assay readout over the logarithm of the inhibitor concentration. All curve fits were performed with the program Prism 3.0 (Graphpad Software, San Diego, CA).
Identification of protein kinase A substrates by chemiluminescence
To test a library of 720 peptides distributed on two 384-well plates (Jerini, Berlin, Germany) as substrates for protein kinase A (PKA) in the chemiluminescent ATP consumption assay, a mastermix containing all assay components except the substrate was prepared by mixing 2.4 ml of 9 U/ml PKA catalytic subunit (Upstate Cat. No. 14-440; in 30 mM potassium phosphate pH 7.4, 1 mM EDTA, 150 mM KCl, 1 mM DTT, 50% [v/v] glycerol) with 2.4 ml 20 mM MOPS•KOH pH 7.2, 5 mM EGTA, 1 mM Na 3 VO 4 , 1 mM DTT, and 960 µl 7.5 µM ATP in 20 mM MOPS•KOH pH 7.2, 150 mM MgCl 2 , and each well of a white polystyrene 384-well plate from Greiner (Cat. No. 784075) was filled with 12 µl of this mastermix. Subsequently, 3 ml of a 10-µM solution of the peptide stock solutions from the library was added with a Biomek FX (Beckman Coulter International, Zürich, Switzerland), followed by a 2-h incubation at 30° C. As controls, wells containing 3 µl of a 10-µM solution of the known PKA substrate Biotin-LCGRTGRRNSI-NH2 (Upstate Cat. No. or no peptide at all were run in parallel. After addition of 15 µl Kinase-Glo reagent (Promega Cat. No V6174) and a further 10 min of incubation at room temperature, luminescence was read on an Analyst GT in luminescence mode (1 s/well, attenuator out, CV 1%, Z height 1 mm).
Identification of PKA substrates by FP
For identification of substrates by the FP assay, 10 µl of 200 µM ATP in 20 mM MOPS pH 7.2, 5 mM EGTA, 1 mM Na 3 VO 4 , 1 mM DTT, 40 mM MgCl 2 was mixed with 10 µl of 6 U/ml PKA catalytic subunit (Upstate Cat. No. 14-440, obtained through Lucerna Chem, Luzern, Switzerland) in 30 mM potassium phosphate pH 7.4, 1 mM EDTA, 150 mM KCl, 1 mM DTT, 50% (v/v) glycerol in the wells of a 96-well IMAP substrate finder plate 1 (Molecular Devices Cat. No. R7328). After incubation for 2 h at 30° C, 60 µl of a 1:400 dilution of IMAP beads in 100% binding buffer was added, and after a further incubation for 60 min at room temperature, polarization was measured on the Analyst GT in FP mode (lamp continuous, excitation filter 485-25, emission filter 530-25, dichroic 505, target SD 1 mP, raw data counts/s, attenuator out, Z height middle of well/2.5 mm).
RESULTS AND DISCUSSION
To be suitable for miniaturized HTS on a routine basis, an assay technology has to be homogeneous to circumvent complicated and error-prone transfer steps. In addition, the environmental and safety problems associated with radioactive waste favor the use of nonradioactive methods wherever possible. As all of the technologies discussed in this report fulfill these criteria, the comparison will focus on the need for reagent, the possibility to miniaturize assays, and their susceptibility to compound interference. However, the arguably most important concern in the development of HTS assays is or should be the sensitivity toward inhibitors of the respective molecular target.
In the comparative study described here (summarized in Table 1 and discussed in more detail below), the major determinant for assay sensitivity as measured with the nucleotide analogue staurosporine was the concentration of ATP. However, an increase of the kinase concentration also lowered the sensitivity, although this effect was more pronounced in the TR-FRET than in the direct FP readout. Nevertheless, we could configure sensitive assays with all 3 readouts as demonstrated by the similar IC 50 values of approximately 10 nM under optimized conditions. However, this was possible only by considering the specific characteristics of each assay format.
At least for competitive inhibitors, the Cheng-Prusoff equation describes the quantitative relationship between the IC 50 value, which is defined as the concentration resulting in 50% inhibition of a particular assay, and the assayindependent K i value, which describes the binding affinity of the compound and target under examination. To apply this formula, the K M value for the respective substrate either needs to be known from the literature or has to be measured during assay development. To this end, the reaction velocity at different substrate concentrations should be determined only from the linear phase of the reaction, and this has to be verified by recording time courses rather than inferring velocities from single time-point measurements. Also, in our experience, the K M can be influenced by the labeling or biotinylation of the substrate peptides and therefore is preferentially determined in the readout that is going to be used for the subsequent screen.
Concentration of ATP
For kinases, by definition 1 of the 2 substrates is ATP, and its concentration can have a significant influence on the sensitivity of an assay toward ATP analogues such as staurosporine. Figure 2B shows the approximately 10-fold shift in IC 50 observed upon raising the ATP concentration from 10 µM, which roughly equals the K M value of 11.6 µM ( Fig. 2A) , to 100 µM or 10× K M . Because the dominant factor in the Cheng-Prusoff equation is not so much the absolute concentration of a substrate but rather the ratio of its concentration to the corresponding K M value, it is necessary to determine the K M for each kinase separately and choose the ATP concentration accordingly if maximal sensitivity is desired. On the other hand, deliberately choosing an ATP concentration far above the K M can be a means to bias the outcome of the HTS against ATP analogues, which typically are very well represented in pharmaceutical compound libraries, and to focus the screen on other types of inhibitors such as analogues of the cosubstrate (protein, peptide, or small molecule) or allosteric modulators, which occasionally also can be derived from HTS. 23 Last but not least, an informed choice also needs to consider that cellular ATP concentrations are between 1 mM and 5 mM, 24 which is one reason why compounds can show a more pronounced effect in biochemical than in cell-based kinase assays.
Although these fundamental biochemical relations are not dependent on the readout used, the ease with which assay conditions can be adapted to the enzymology of a particular target varies. For example, the concentration of ATP can be varied as appropriate if the readout is TR-FRET ( Fig. 1, right) , which is only indirectly influenced by ATP. In contrast, chemiluminescence measures kinases through their consumption of ATP ( Fig. 1, left) , which restricts the range of practical concentrations. On one hand, the ATP concentration needs to be high enough to achieve a sufficient signal as well as a significant reaction velocity and therefore is dependent on the sensitivity of the reader and the kinetic parameters of the kinase. On the other hand, the cosubstrate to be phosphorylated limits the amount of ATP that can be consumed, and therefore, the technology seems most suitable for kinases whose K M value for ATP is lower than that for the cosubstrate. In addition, excessive ATP concentrations necessitate high amounts of enzyme to achieve significant changes in readout (vide infra) and can jeopardize the linearity of the luciferase signal when used above 12.5 µM. 19 Although the FP signal of the IMAP readout originates from the peptide (Fig. 1, middle) and therefore is not directly dependent on ATP concentration, ATP can compete with the binding of phosphopeptide to the IMAP beads 25 and should not be used at concentrations above 30 µM, 26 although a modified ("progressive") IMAP system reportedly is less affected. 18 Nevertheless, the K M value of 5.4 µM, that we determined with the IMAP technology for kinase 1 (data not shown), is fairly close to the 12 µM, which we determined in the FRET readout ( Fig. 2) , indicating that this effect is not a major limitation for kinases with K M values in this concentration range.
Concentration of the substrate to be phosphorylated
Although the Cheng-Prusoff equation applies to the protein, peptide, or small molecule that is phosphorylated in the kinase reaction as well as to ATP, this is difficult to test experimentally because only few compounds that clearly compete with a kinase substrate other than ATP have been described. 27, 28 Nevertheless, it is important to consider the K M value when choosing a substrate, although its determination is not always straightforward, as the various readout systems themselves can be influenced by the substrate concentration. Again, the TR-FRET readout is most flexible, as it measures exclusively the product of the reaction. This makes it possible to vary the peptide substrate almost at will. The only limitation is the amount of the streptavidincoupled allophycocyanin acceptor, which has to be sufficient to bind all of the biotinylated peptide (substrate and product) but also defines the background signal. In contrast, the chemiluminescence assay inherently requires an excess of substrate over ATP, which can make it difficult to determine K M values or to maximize sensitivity for high-affinity substrates (i.e., when the K M for the substrate is significantly lower than that for ATP).
On the other hand, the K M values for low-affinity substrates that we determined generally were in good agreement with those in the literature (data not shown); therefore, this readout might be most suitable for kinases with weakly binding substrates such as low-molecular-weight metabolites. Unlike the conventional, competition-based FP assay that uses an unlabeled substrate that does not contribute to the signal, 8, 14, 16 the direct FP assay uses a fluorescently labeled substrate. Because the readout reflects the ratio of product to substrate rather than the absolute amount of product formed, polarization (or anisotropy) values measured in the reaction need to be converted to product concentrations based on the polarization of unphosphorylated and fully phosphorylated peptide before a K M value can be calculated. This is demonstrated in Figure 3 , which shows time courses of FP measured for different concentrations of kinase 1 and TAMRA-labeled crosstide.
For each of the 4 tested substrate concentrations, FP (expressed in mP) increased with increasing enzyme concentration (Figs. 3A-D). Although substrate concentrations varied by 3 orders of magnitude, time courses of FP over time were almost indistinguishable for a given enzyme concentration. Presumably, the acceleration of the reaction at higher substrate concentrations was compensated by the larger amount of peptide that needed to be processed to achieve a certain change in polarization. Only at the highest tested substrate concentration of 10 µM (Fig. 3D) was the polarization increase slightly slower, presumably because the relationship between reaction velocity and substrate concentration is not strictly linear above the K M , which was determined as 6.9 µM by calculating the absolute peptide concentrations for different conditions and time points ( Fig. 3E) and then plotting the reaction velocity as a function of substrate concentration (Fig. 3F) .
Concentration of enzyme
Apart from choosing the appropriate substrate concentrations, it is critical to ensure that the readout faithfully reflects enzyme activity in the test sample. Ideally, the measurement should be taken during the linear phase of the assay time course, that is, at a time when the readout signal is linearly related to the product formed or the substrate consumed. In reality, true linearity is often limited to small readout changes during the initial reaction phase. We observed this especially for those readouts that measure not the formation of a reaction product but rather the ratio of product to educt (e.g., the direct FP assay; Fig. 3 ) or the consumption of an educt. In particular, time courses of the kinase reaction measured in the chemiluminescence format (Fig. 4A) showed a constant decrease in slope with only a small linear phase at the very beginning of the reaction. Unless the enzyme is completely saturated with its substrates (which, as discussed above, would in itself reduce sensitivity), reaction velocity is a function of substrate concentrations and therefore inherently decreases as the reaction progresses, resulting in 1st-order kinetics. Although this sometimes necessitates compromises between strict linearity and the need for a certain dynamic range, 29 it is essential to avoid assay conditions under which the correlation between signal and activity is completely compromised. For example, the TR-FRET readout is limited by the amount of antibodies in the detection mix, and therefore the signal we observed upon titration of the kinase (Fig. 5A) was linearly related to small enzyme concentrations but showed a plateau at higher enzyme concentrations. This difference had profound effects on assay sensitivity-a doubling of the enzyme concentration shifted the IC 50 value approximately 4-fold ( Fig. 5B) -because under detection-limited conditions, the signal hardly changes at all unless a large portion of the enzyme molecules is inhibited. We observed a similar relationship of assay sensitivity and enzyme concentration for the chemiluminescence readout (Fig. 5C, D) , although the effect in this case originated from the nonlinear kinetics of the reaction: As the ATP concentration decreases, the kinase reaction slows down, and inhibition of the enzyme has relatively less and less effect on the assay signal. Both readout saturation and nonlinear progress curves can be prevented by reducing either enzyme concentration or reaction time. These 2 parameters should therefore be optimized simultaneously, for example, by recording time courses at various enzyme concentrations (Figs. 3, 4) . Independently of the readout time, the enzyme concentration also constitutes a lower limit for the compound affinities that can be resolved by the assay, as compound depletion reduces the inhibition that can be observed at higher dilutions.
The assumption that the concentration of "free" or unbound compound roughly corresponds to the total amount added to the experiment, which forms the basis for the Cheng-Prusoff approach, is no longer valid when a significant proportion of the compound is bound to the enzyme. For example, kinase 2 was employed at a protein concentration of 3 µg/ml or 75 nM, and in principle, this should prevent the assay from distinguishing between a compound with 1 nM affinity and one with 10 nM, as both would yield similar IC 50 values. In practice, one cannot assume that all of the protein in the preparation constitutes correctly folded, catalytically active kinase, and the actual limit most likely is significantly lower. For example, all of the assay formats yielded similar staurosporine sensitivities for kinase 1 despite vast differences in the amount of enzyme required to achieve a comparable signal change ( Table 1) . Therefore, this compound depletion effect 30 should be significant only for kinases with very low activity or for inhibitors with very high affinity. These are not routinely found in primary screening, which typically is conducted at micromolar compound concentrations.
Reagent supply
Enzyme consumption is an important-sometimes even critical-factor for the success of HTS campaigns, as the increasing size of compound libraries more than compensates for the savings from miniaturization to the 1536-well format. Moreover, many kinases are difficult to produce in active form even when using eukaryotic expression systems. Equally important is a cost-effective supply of the other reagents. In our experience, there is a trade-off between the amount of enzyme needed and the costs of the reagents that are required to measure its activity ( Table 2) , so no clear advantage of one over the other method could be established.
In addition to the quantity, the quality of the available reagents also influences the applicability of a particular readout. In the IMAP-based direct FP assay, for example, some batches of kinase 2 could not increase the polarization of the substrate peptide to the expected levels or even decreased the polarization of the fluorescently labeled reference phosphopeptide (data not shown), indicating a possible contamination either with phosphatase activity or with a substance that prevents binding of phosphopeptide to the beads (e.g., inorganic phosphate). Similarly, the luminescence assay format is very sensitive to contamination of the kinase preparations with other ATPases. At least in initial activity measurements, appropriate controls lacking the substrate to be phosphorylated need to be run for every batch of enzyme so that kinase-independent ATP degradation can be assessed. 19 Figure 6A shows the results of testing 2 representative batches of kinase 3, in one of which (sample 7) an unspecific ATPase activity was detected at the highest tested concentration, whereas the other (sample 8) did not contain such a contamination. In addition, luciferase is Using a Cartesian Synquad, 3 µl of kinase 1 diluted in its reaction buffer was mixed with 0.5 µl 3.5 µM substrate peptide, 70 µM ATP in the same buffer, and incubated at room temperature for the indicated time. After addition of 0.5 µl of the described detection mixture, the plate was incubated for a further 60 min and read on the Analyst GT as described. Indicated enzyme concentrations refer to the reaction mixture before addition of detection reagents. sensitive to NaCl, 31 which can pose a problem if salt is required for the stability of the enzyme. The various commercially available luciferase/luciferin preparations also need to be carefully evaluated with regard to both the strength of the luminescence signal and its stability over time. These 2 factors are not directly correlated, as the luminescence signal we obtained with reagent 1 was much larger than that obtained with the other 2 preparations ( Fig. 6B , main graph) but decayed more rapidly over time even when diluted to a comparable signal strength (Fig. 6B,  insert) . Such a rapidly decaying signal can result in drifts over the plate, thus complicating the evaluation of screening results, and should be avoided even at the price of reduced luminescence intensity, which usually is not a limitation for modern, sensitive readers.
Miniaturization
The assay technologies examined in this study were selected because they offered the potential for miniaturized screening.
Overall, this expectation proved to be correct; however, there was a specific learning curve associated with miniaturizing each of the readouts from a 96-or 384-well format toward the desired 1536-well format.
One of the first experiments during miniaturization of an assay is to check whether the reagent concentrations and incubation time selected for the nonminiaturized assay (384-and 96-well formats) can be applied also in the miniaturized format. An example can be found in Figure 7A , which shows the luminescence signal of all 1536 wells on an assay plate, onehalf of which were filled with reagents 30 min after the other, resulting in incubation times of 60 or 90 min before addition of the luciferase/luciferin mixture. In this particular assay, 60% to 70% of ATP was already consumed after 60 min, which therefore was chosen as the incubation time for compound screening instead of the 90 min also tested. Usually, such minor adaptations are sufficient; if there are larger variations, a systematic permutation of automatically dispensed and handpipetted assay components can help to identify which of them causes the differences between miniaturized and nonminiaturized format. This is the basis for appropriate countermeasures, such as, adding detergents to prevent adsorption of assay reagents to dispenser reservoirs or tubing.
At the same time, the uniformity of the readout over a whole plate needs to be ensured. For example, IMAP beads tended to settle within the tubing of automated dispensers, which could be overcome by thorough rinsing before filling a plate. As shown in Figure 7B , this resulted in an even assay signal in both fully active samples and samples without enzyme, albeit at the price of increased reagent consumption. Occasionally, we observed drift effects also in the luminescence readout if the order and speed of dispensing was not synchronized with that of reading (data not shown); to minimize them, we routinely checked the stability of the signal obtained from a particular reagent preparation. Ideally, such experiments are already done in the layout and with the controls that are later used for actual screening of compounds. In addition, it is very important to simultaneously determine both dynamic range and assay statistics. This is best done by filling whole plates with an equal number of "high" wells (i.e., wells containing the complete assay setup but no compounds) and "low" wells (which either contain a reference inhibitor or simulate its effect by omission of a critical assay component). Figure 7 illustrates the result of such an experiment for the FP (Fig. 7B) and TR-FRET ( Fig. 7C) readouts, respectively. In this way, the Z′ value, which is the most widely used measure of assay quality, 32 can be determined much more reliably than from the limited number of control wells, which are much more affected by individual outliers. The Z′ values should be 0.5 at a minimum and if possible higher to minimize false positives caused by statistical variation. Typically, the Z′ values observed using the final 1536-well assay protocols were about 0.6 for the direct FP assay (Fig. 7B) , 0.7 in the chemiluminescence format (data not shown), and 0.8 for the TR-FRET readout (Fig. 7C) .
The assay signal can vary not only across plates but also in time. For example, the full dynamic range of the IMAP-based direct FP assay was reached 30 min after the kinase reaction had been stopped by addition of the IMAP beads (data not shown). However, measuring 60 min after bead addition typically produced better assay statistics because of lower variation of the signal (see Fig. 7B for an example). Occasionally, individual wells on 1536-well plates showed prolonged equilibration times compared to the remainder of the plate, sometimes even showing a temporary drop of polarization to the levels observed in controls without enzyme. Although this phenomenon, which might be related to air bubbles or uneven mixing, 17 can be annoying, it disappeared after prolonged incubation. No loss of dynamic range was observed up to 24 h after addition of the IMAP beads (data not shown), indicating that this readout is very stable and therefore also suitable for batch mode operation. The need to assess signal stability when selecting a luciferase/luciferin preparation has already been discussed.
Of critical importance for an efficient screen is the stability of reagents in dispenser reservoirs. Carefully optimizing this minimizes both the need for manual refilling during automated screening runs and the loss of reagents associated with rinsing and refilling. For example, in the TR-FRET readout, we observed a loss of donor signal at 615 nm after prolonged reservoir incubation of the detection mix ( Fig. 8) . Systematic variation of Plotted on the z axis is the polarization as a function of well coordinates. The enzyme was replaced by the respective buffer in half of the wells. The large number of controls produced in this way allows one to reliably determine both dynamic range and standard variations and to calculate an accurate Z′ value (in this example, 0.75). Columns 45 and 46 also contain controls with and without enzyme, respectively, as would a plate during screening of unknown compounds. (C) Time-resolved fluorescence resonance energy transfer signal measured in the presence or absence of kinase 1. Plotted on the z axis is the acceptor-todonor ratio as a function of well coordinates. The enzyme was replaced by the respective buffer in half of the wells. This allows one to assess both the dynamic range (i.e., the difference between wells with and without enzyme) and the uniformity (variation within areas with or without enzyme) of the assay. The Z′ value in this example was 0.88. Columns 45 and 46 also contain controls with and without enzyme, respectively, as would a plate during screening of unknown compounds. the reservoir solution identified EDTA, which had been included in the detection mix to fully stop the kinase reaction, as the cause of the problem. Therefore, the protocol was slightly modified by introducing a separate pipetting step for addition of EDTA. Thus, the detection reagents are not exposed to the high EDTA concentrations in the reservoir but only to the much lower concentrations in the plate and therefore were stable for at least 8 h in the reservoirs of the nanodispenser, which minimized the need for refilling during screening runs.
Compound interference
To compare the sensitivity of the various readouts to compound interference, the kinase assays were performed in the presence of dyes with different excitation and emission maxima (Fig. 9A) . Although all readouts showed some interference, there were clear differences that mostly relate to the wavelengths that are used in the assay. For example, as the FP assay used a substrate peptide labeled with TAMRA, this dye decreased the polarization significantly and would have been identified as a false positive in the screen (Fig. 9C) . Wavelength-dependent autofluorescence of compounds has also been identified by others as the main reason for compound interference with the IMAP readout. 33 Despite the time-delayed measurement and statements by the vendors of the appropriate assay kits, the TR-FRET readout also was clearly influenced by dyes such as Cy5 and MR121, whose spectra overlapped those of the FRET acceptor (Fig. 9B) .
In contrast, an effect of dyes on the chemiluminescence readout was visible only at concentrations of 10 µM and higher and did not show a clear wavelength dependence (Fig. 9D) .
On the other hand, the chemiluminescence readout is not ratiometric and therefore does not offer the possibility to identify or correct for compound interference by analyzing the raw signals in the 2 channels as is possible for the ratiometric TR-FRET and FP readouts. Rather, potential artifacts need to be excluded by counterscreens or secondary assays. 19 In our hands, most of the compounds identified by screening with a luminometric assay could be confirmed in radioactive secondary assays (data not shown).
Interestingly, interference by fluorescent compounds led to an overestimation of kinase activity and hence a potential for false negatives during screening in the TR-FRET readout but an underestimation of kinase activity with the potential for falsepositive screening hits in the direct FP readout, whereas the direction of the effect varied for the chemiluminescence readout. Together with the differences in wavelength dependence, this suggests that the combination of several readouts to assess a compounds inhibitory effect should significantly increase the reliability of screening results.
Substrate identification
For many novel kinase targets, especially those derived from genomics, neither the best nor the natural substrate is known at the start of a drug discovery program. This makes it necessary to identify an appropriate surrogate substrate, ideally in one of the antibody-independent readouts. We therefore evaluated this possibility with both the chemiluminescent and the IMAP readout using PKA as a model enzyme. From a library of 720 peptides, the chemiluminescent assay identified 6 peptides that induced an ATP consumption comparable to the known PKA substrate LCGRTGRRNSI (shown in Table 3 peptides with a partial ATP consumption, whereas 670 peptides had no significant effect. The random distribution of the identified substrate peptides in the library on the 2 plates is shown in Figure 10A . From the 50 peptides that induced ATP consumption, 90% had arginine at the -3 position, 80% had arginine at the -2 position, 25% had an arginine at the -4 position, and 50% had an aliphatic amino acid at the +1 position. These results agree well with the consensus sequence for an "optimal" PKA substrate (RRRRSIIFI 34 ), which also contains arginine residues at positions -2 and -3. There was also some overlap with the results obtained for the same peptide library in a radioactive format, 35 although the latter identified more peptides and appeared less stringent. In parallel, the IMAP technology was evaluated with a commercially available collection of 56 fluorescein-labeled substrates. For 2 of them, which matched the known PKA consensus ( Table 3) , incubation with PKA clearly increased the polarization observed after addition of IMAP beads (Fig. 10B) . However, basal polarization values of the fluorescent peptides varied significantly even without kinase-induced phosphorylation, probably reflecting the influence of the peptide sequence on nonspecific binding to the IMAP beads. 17 Therefore, further optimization of both reaction and binding buffer would be necessary during assay development.
CONCLUSIONS
Both methodical studies and experiences with real drug discovery targets over several years show that sensitive kinase assays can be developed in the 1536-well format not only with antibody-dependent methods but also with the antibodyindependent chemiluminescence or FP readouts. None of the technologies discussed here is generally superior over the others; rather, the most appropriate readout needs to be selected for each kinase target individually. Besides the availability, quality, and cost of the necessary enzymes and reagents, which in practice can limit the available choices, the enzymology of the respective kinase, in particular the K M values for both ATP and the substrate, and the specific needs of the respective drug discovery program should drive this decision.
Whereas all readouts suffer from some degree of compound interference, they do not suffer in the same way ( Fig. 9) . As shown in Figure 11 , compounds that were identified as inhibitors of kinase 2 in the TR-FRET assay typically showed also high inhibition values in the direct FP assay, whereas compounds classified as inactive based on the TR-FRET assay showed little or no inhibition in the FP assay. This indicates that "true" inhibitors will show up regardless of the readout, and therefore the parallel use of multiple readouts, for example, during hit validation, should allow the elimination of readoutspecific artifacts.
Kinase substrates can be identified with both the chemiluminescence and the direct FP readout (Fig. 10) ; this is ideally done with the readout that is going to be used later for assay development and screening. Especially for serine/threonine kinases without a known substrate-antibody combination, these methods are therefore valuable alternatives to more mature but antibody-dependent technologies such as TR-FRET.
Nevertheless, none of the readouts discussed here is perfect under all conditions and for all kinases. Therefore, the portfolio of technologies used to screen for kinase inhibitors can be expected to grow further both through the optimization of existing formats, for example, coupled enzyme assays, 36 and through the development and evaluation of novel readouts such as biosensors based on RNA aptamers 37 or nucleotide-converting enzymes. 38 
